Quality control to improve LDL-cholesterol management in patients with acute coronary syndromes based on the acute coronary syndrome (ACS) EuroPath IV project
Authors' conclusion
Quality control for LLT, based on the ACS EuroPath IV survey, detected 10 potential changes in prescription that could enhance attainment of 2 QIs.
Study context
- Population
- Patients with ACS, European cardiology centres530 cardiologists
- Outcome
- Attainment of 2 LLT quality indicators: (i) high-intensity statin (or equipotent) prescribed before discharge; (ii) LDL-C <55 mg/dL (1.4 mmol/L) during follow-up
Methodological detailsDefine Measure Analysis Improve Control (DMAIC) approach, multicentre (European)
- DMAIC approach
- Multicentre (European)
Main finding
As reported in the abstract
Attainment of LLT quality indicators (QIs)
First QI attained: high-intensity statin (or equipotent treatment) prescribed before discharge, in 929 acute-phase patients
75%
Second QI attained: LDL-C <55 mg/dL (1.4 mmol/L) during follow-up, in 1721 patients with follow-up
31%
Observational data: associations, not effects.
Further findings
Lipid-lowering therapy (LLT) prescribed at discharge
- LLT prescribed at discharge, in 929 acute-phase patients
- 99%
Potential prescription changes identified by DMAIC
- Total potential changes in prescription
- 10
- Potential changes for the first QI
- 3
- Potential changes for the second QI
- 7
Original publication
Quality control to improve LDL-cholesterol management in patients with acute coronary syndromes based on the ACS EuroPath IV project. Eur Heart J Acute Cardiovasc Care. Published 13 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →